Publikationssuche

    Unsere Forschungs- und Entwicklungsteams sind weltweit im Einsatz und generieren Synergien aus unserem Expertenwissen und verwandten Fachdisziplinen. Wir stehen im internationalen Austausch mit unabhängigen Fachinstitutionen, Key Opinion Leadern und Multiplikatoren, um so Kooperations- und Wissensmanagement auf höchstem Niveau gewährleisten zu können. Im Rahmen dessen führen wir umfangreiche Forschungen durch, die kontinuierlich auf Kongressen in Form von Postern oder freien Vorträgen unserer Kooperationspartner sowie in Symposien und Workshops präsentiert und in namhaften wissenschaftlichen Fachzeitschriften veröffentlicht werden. Die größtenteils von unabhängigen Gutachtern bewerteten, evidenzbasierten Fachpublikationen, stellen wir Ihnen in dieser Datenbank zur Verfügung:

    1. Journal article

      A prospective randomised trial of four-layer versus short stretch compression bandages for the treatment of venous leg ulcers

      Annals of the Royal College of Surgeons of England 1998 80(3) 215220

      This trial was undertaken to examine the safety and efficacy of four-layer compared with short stretch compression bandages for the treatment of venous leg ulcers within the confines of a prospective, randomised, ethically approved trial. Fifty-three patients were recruited from a dedicated venous ulcer assessment clinic and their individual ulcerated limbs were randomised to receive either a four-layer bandage (FLB)(n = 32) or a short stretch bandage (SSB)(n = 32). The endpoint was a completely healed ulcer. However, if after 12 weeks of compression therapy no healing had been achieved, that limb was withdrawn from the study and deemed to have failed to heal with the prescribed bandage. Leg volume was measured using the multiple disc model at the first bandaging visit, 4 weeks later, and on ulcer healing. Complications arising during the study were recorded. Data from all limbs were analysed on an intention to treat basis; thus the three limbs not completing the protocol were included in the analysis. Of the 53 patients, 50 completed the protocol. At 1 year the healing rate was FLB 55% and SSB 57% (chi 2 = 0.0, df = 1, P = 1.0). Limbs in the FLB arm of the study sustained one minor complication, whereas SSB limbs sustained four significant complications. Leg volumes reduced significantly after 4 weeks of compression, but subsequent volume changes were insignificant. Ulcer healing rates were not influenced by the presence of deep venous reflux, post-thrombotic deep vein changes nor by ulcer duration. Although larger ulcers took longer to heal, the overall healing rates for large (> 10 cm2) and small (10 cm2 or less) ulcers were comparable. Four-layer and short stretch bandages were equally efficacious in healing venous ulcers independent of pattern of venous reflux, ulcer area or duration. FLB limbs sustained fewer complications than SSB.

      Products Rosidal K
      PMID 9682649
      Downloads Citation (RIS)
    2. Journal article

      Die "Fischer-Verbände" Teil III: Der Druckverband nach Heinrich Fischer*

      Vasomed 1997 9(6) 378380

      Die Kompressionstherapie bleibt eine entscheidende Säule der Phlebologie. Der therapeutische Zentralsatz lautet: Heilphase mit nicht nachgiebigen Verbänden -Erhaltungsphase mit elastischem Material (Kompressionsstrumpf). Indikationen, Anlagetechnik und das Verbandmaterial für den ein-fachsten der »Fischer-Verbände«, den Druckverband, wird aufgezeigt. Dieser kann vom Patienten nach Anleitung selbst gewickelt werden.

      Products Dauerbinde K
      Downloads Citation (RIS)
    3. Journal article

      Die "Fischer-Verbände"*

      Vasomed 1996 8 265269

      Die ambulante Therapie der tiefen Beinvenenthrombose erlebt eine Renaissance. Durchgeführt wird sie mit Kompressionsverbänden nach Heinrich Fischer. DieTechnik und das Material für den nicht nachgiebigen und den nachgiebigen fixierten Unterschenkel-Kompressionsverband werden vorgestellt.

      Products Porelast
      Downloads Citation (RIS)
    4. Poster

      Observational, international, multicentre, single-arm study to assess the performance, safety and handling of new antimicrobial hydroactive fibre dressing

      Poster presented at Wounds UK Conference 2023 06.11.2023 Harrogate, UK

      Introduction

      Infected or infection-prone wounds are a challenge in wound care, requiring effective infection management and wound exudate control. [1] A new antimicrobial hydroactive fibre dressing* containing silver nanoparticles was developed for these needs. This study aimed to assess the product's performance, safety, and usability in managing such wounds.

       

      Methods

      The clinical study took place at 6 centres in Germany (n=5) and Austria (n=1). Eight wound managers treated 81 patients (46% male/54% female) with the investigated product, performing at least 4 dressing changes over 7 to 28 days as per instructions. Results were collected via an electronic questionnaire. Patients' average age was 66.88 ± 16.17 years. The study adhered to the declaration of Helsinki and complied with §3 clause 4 of the German Medical Devices Act (MPDG) and §47 Section 3 of the MPDG.

       

      Results

      The study included patients with various medical conditions, such as venous leg ulcers (24.69%), postoperative wounds (13.35%), second-degree burns (12.35%), pressure injuries (12.35%), diabetic ulcers (12.35%), traumatic wounds (12.35%), and wounds prone to bleeding (12.35%). Among these wounds, 41% were deep, and 59% were superficial. Regarding exudation, 75% had a moderate level, while 25% had a high level. Over the study period, signs of infection such as redness, overheating, tissue dysfunction, swelling, pain, and wound odour were significantly reduced by an average of 2.64 on the Visual Analog Scale (VAS). Biofilm was no longer visible in 60% of the treated wounds that initially showed visible biofilm at the beginning of the treatment. In 31% of cases, biofilm was still partially visible. On average, practitioners successfully achieved their treatment goals, including maintaining wound moisture, facilitating autolytic debridement, protecting the wound edge from maceration, supporting wound healing, managing exudate, controlling existing infections, and preventing new infections. These goals were achieved at a rate of 95.3% through the use of the investigated wound dressing. In 100% of the wounds, the gelled wound dressing effectively removed cellular debris from the wound. The dressing conformed to the wound in 98.8% of cases. Only 3.7% of the wounds experienced gelation extending beyond the wound's edge, and wound exudate spread beyond the wound edge in only 26% of cases. Maceration was caused by the dressing in only 2.5% of cases. In all cases, wound exudate was successfully directed into the secondary dressing. The dressing could be removed intact in every case. In 12.4% of cases, easily removable fibre residues remained in the wound. The dressing adhered to the wound bed in 5% of cases. Dressing changes were atraumatic in all cases, and the dressing could be cut to fit the wound in every instance.

       

      Discussion

      It has been demonstrated that the tested wound dressing is capable of providing excellent support to the user in treating infected or infection-prone wounds. Pre-existing infections could be reduced or entirely eliminated. Effective exudate management was facilitated, and wound edges were protected from maceration. Additionally, atraumatic dressing changes, without the product falling apart, contributed to wound healing.

       

      Conclusion

      This study demonstrated that the new wound dressing is highly suitable for the management of infected or infection-prone wounds. The presented study provides insights into the product's performance under real-life conditions. Further prospective randomized studies are necessary to gain a more comprehensive understanding of the product's capabilities.

       

      *Suprasorb® Liquacel Ag - Speciality Fibres and Materials Ltd

      Further versions
    5. Poster

      Antibiofilm performance of silver nanoparticles and new silver nanoparticle wound dressing

      Poster presented at SAWC Spring 2023 26.04.2023 National Harbor, United States

      Introduction:

      A new, non-silver cellulose-based wound dressing has demonstrated to be effective against biofilms and preventing bacterial penetration. The fibres of the new dressing are coated with a novel antibiofilm formulation containing PHMB (polyhexanide).

      Methods:

      The biofilm method used in the study was based on a gauze model developed by Bowler and Parsons, 2016. 1 In the first step, circular pieces of 1.6 cm sterile gauze were punched out before being transferred into sterile 100 ml Erlenmeyer flasks and submerged in 25 ml of liquid bacterial culture containing either S.aureus or P.aeruginosa at approximately 1-5 x 105 CFU/ ml. The Erlenmeyer flasks were subsequently shaken for 48h in order to coat the gauze with a mature biofilm.

      Each piece of gauze was then placed onto an individual agar plate and covered with a 3.2 cm disk of the test dressing and wetted with 1.5 ml of simulated wound fluid. Finally, the test dressings were covered with a piece of silicon dressing and the plate closed with parafilm.

      Bacterial penetration testing was performed by saturating 4.2 x 4.2 cm dressing samples with aliquots of SWF. Dressings were subsequently incubated (pre-conditioned) at 37°C for 6-days. After this period, the cut samples were placed onto fresh agar plates and inoculated with bacterial suspension containing 1x 108 CFU/ml evenly around the edge of the dressing. Petri dishes were then incubated for 24h, the dressings removed and plates inspected for growth.

      Results:

      The new, non-silver wound dressings completely killed all the bacteria in the both the S. aureus and P.aeruginosa biofilms. In comparison, a silver based competitor dressing did not remove the biofilm for either bacteria.

      Bacterial penetration was also prevented in the new dressing.

      Discussion:

      Initial evidence would suggest the new non-silver dressing is highly effective against biofilms and preventing bacterial penetration.

    6. Poster

      The outcomes of a new reusable fibreglass and polyester combined total contact cast system (Cellacast Lohmann and Rauscher) in the management of plantar ulcers

      Poster presented at EWMA 2023 03.05.2023 Milan, Italy
    7. Poster

      Observational, multicentre, single-arm study to assess the performance, safety and handling of new antimicrobial calcium alginate dressing

      Poster presented at Wounds UK Conference 2023 06.11.2023 Harrogate, UK

      Introduction

      Wound care becomes challenging when dealing with infected or infection-prone wounds, demanding both effective infection control and proper management of wound exudate. [1] To address these challenges, a novel antimicrobial calcium alginate dressing was developed. The objective of this study was to evaluate the dressing's performance, safety, and ease of use in the treatment of such wounds.

       

      Methods

      The clinical study was conducted across 5 centres in Germany. Wound managers treated 91 patients (46% male/54% female) with the investigated product, following instructions for a minimum of 4 dressing changes over a 7 to 28-day period. Data was collected using an electronic questionnaire, and the patients had an average age of 69.46 ± 16.38 years. The study followed the principles of the Declaration of Helsinki and adhered to §3 clause 4 of the German Medical Devices Act (MPDG) and §47 Section 3 of the MPDG.

       

      Results

      The study included patients with various medical conditions, such as venous leg ulcers (23.08%), postoperative wounds (23.08%), pressure injuries (20.88%), diabetic ulcers (10.99%), arterial ulcer (10.99%), and skin graft or donor sites (10.99%). Among these wounds, 42% were deep, and 58% were superficial. During the study period, indicators of infection such as redness, overheating, tissue dysfunction, swelling, and pain were significantly reduced by an average of 1.34 on the Visual Analog Scale (VAS). On average, practitioners effectively met their treatment objectives, which encompassed maintaining wound moisture, facilitating autolytic debridement, protection of the wound edge against maceration, supporting wound healing, managing exudate, controlling existing infections, preventing new infections, and stopping bleeding. These objectives were achieved at a 94% success rate with the use of the examined wound dressing. In only 7.7% of cases did the wound dressing fail to gel. In 98.9% of cases, the wound remained fully covered after the dressing had gelled. The gelled wound dressing effectively removed cellular debris from the wound if present in 97.01% of cases. The dressing conformed to the wound in 98.9% of instances. Maceration resulted from the dressing in only 1.1% of cases. Wound exudate was effectively channelled into the secondary dressing in 97.2% of all cases. In 97.8% of cases, the dressing could be removed in one piece. Easily removable fibre residues were observed in 10.99% of cases. Adherence of the dressing to the wound bed occurred only in 4.4% of cases. Dressing changes were atraumatic in 97.8% of cases. The ease of use, as well as cutting the dressing when dry, was rated as very easy or easy in 100% of cases.

       

      Discussion

      The study has shown that the tested wound dressing offers valuable assistance to healthcare professionals in the treatment of infected or infection-prone wounds. Existing infections were either reduced significantly or completely eradicated. The dressing also effectively managed wound exudate and safeguarded wound edges from maceration. Furthermore, the dressing's ability to stay intact during gentle dressing changes contributed positively to the wound healing process.

       

      Conclusion

      This study revealed the excellent suitability of the new wound dressing for managing infected or infection-prone wounds. It offers practical insights into how the product performs in real-life situations. To obtain a more comprehensive understanding of the product's capabilities, further prospective randomized studies are required.

       

      *Suprasorb® A + Ag Pro - Speciality Fibres and Materials Ltd

    8. Poster

      Real-world wound debridement: Clinical outcomes and user satisfaction after biofilm pathway management using monofilament fibredebridement technology* over 2 weeks

      Poster presented at WUWHS 2022 01.03.2022 Abu Dhabi, UAE
      Products Debrisoft Pad
      Further versions
    9. Poster

      Mechanical debridement of leg ulcers and the surrounding skin using a monofilament fibre debridement pad designed for larger wounds and surface areas

      Poster presented at WUWHS 2022 01.03.2022 Abu Dhabi, UAE
      Products Debrisoft Pad
    10. Poster

      Surgical treatment of extended keloid scar with dermal substitute, negative pressure wound therapy and partial thickness skin graft: A case study

      Poster presented at WUWHS 2022 01.03.2022 Abu Dhabi, UAE
      Further versions